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Abstract 
The development of a PET radioligand selective for I2-imidazoline binding sites 
(I2BS) would enable, for the first time, specific, measurable in vivo imaging of this 
target protein, along with assessment of alterations in expression patterns of this 
protein in disease pathophysiology.   
Methods: BU99008 was identified as the most promising I2BS radioligand 
candidate, and radiolabelled with carbon-11 via methylation.  The in vivo binding 
properties of 11C-BU99008 were assessed in rhesus monkeys in order to 
determine: brain penetration, brain distribution, binding specificity and selectivity 
(via the use of the unlabelled blockers), and the most appropriate kinetic model for 
analysing data generated with this PET radioligand.  
Results: 11C-BU99008 was demonstrated to readily enter to the brain resulting in a 
heterogeneous distribution (globus pallidus>cortical regions>cerebellum) 
consistent with the reported regional I2BS densities as determined by human tissue 
section autoradiography and preclinical in vivo PET studies in the pig.  In vivo 
competition studies revealed 11C-BU99008 displayed reversible kinetics specific for 
the I2BS. The MA1 multi-linear model was the most appropriate analysis method 
for this PET radioligand in this species.  The selective, I2BS blocker, BU224, was 
shown to cause a saturable, dose-dependent decrease in 11C-BU99008 binding in 
all regions of the brain assessed, further demonstrating the heterogeneous 
distribution of I2BS protein in the rhesus brain and binding specificity for this 
radioligand. 
Conclusion: These data demonstrate 11C-BU99008 represents a specific and 
selective PET radioligand for imaging and quantifying the I2BS, in vivo, in rhesus 
monkey.  Further work is underway to translate the use of 11C-BU99008 to the 
clinic. 
 
Keywords:  Imidazoline2 binding site, I2BS, positron emission tomography, PET, 
BU99008 
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Introduction 
The ability of the α2-adrenoceptor agonist clonidine and the antagonist idazoxan, to 
label a sub-population of binding sites, not displaceable by the endogenous ligand 
noradrenaline, led to the discovery of the imidazoline binding sites some 20 years 
ago.  These binding sites have subsequently been divided into three groups: the 
imidazoline1 binding site that is preferentially labelled by 3H-clonidine, the 
imidazoline2 binding site (I2BS) that is preferentially labelled by 3H-idazoxan, and 
the imidazoline3 binding site which is an atypical imidazoline site found on 
pancreatic β-cells (for review see (1)). 
 
I2BS are known to reside on the mitochondrial membranes of astrocytes (2).  
Changes in post-mortem binding density of the I2BS has implicated them in a 
range of psychiatric conditions such as depression and addiction, along with 
neurodegenerative disorders such as Alzheimer’s disease and Huntington’s chorea 
(3).  Functional interactions in preclinical models have also been shown in relation 
to the opioid system, where I2BS ligands have been shown to affect tolerance to 
morphine (4) and alleviate some of the morphine withdrawal syndrome in rats (5).  
I2BS ligands have also been shown acutely to affect feeding and appetite by an as 
yet undetermined mechanism (6).  The location of I2BS on glial cells and the 
possibility that they may in some way regulate glial fibrillary acidic protein (7) have 
led to increased interest into the role of I2BS and I2BS ligands in conditions 
characterised by marked gliosis.  The density of I2BS has been shown to increase 
in Alzheimer’s disease post mortem (3), and it has also been suggested that I2BS 
may be a marker for human glioblastomas (8).  Subsequent publications added 
weight to this argument showing that the density of I2BS is increased in vivo with 
heat-induced gliosis (9).  Additionally, Callado and coworkers have shown not only 
an increase in the I2BS in human gliomas but this increase in binding sites was 
correlated with the severity and malignancy of the glioma (10).   
 
Positron emission tomography (PET) is an in vivo imaging technique that uses 
radioligands as selective molecular probes to map the location and density of 
specific proteins.  The development of a selective I2BS PET radioligand would 
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allow for the characterisation of I2BS in vivo and their regulation in disease states.  
A number of ligands selective for I2BS have been reported, but only two potential 
PET radioligands have been reported to date: the radiosynthesis of 11C-benazoline, 
but its study in vivo has not been reported (11) and radiosynthesis and in vivo 
imaging evaluation of 11C-FTIMD in non-human primate (12) although the specific 
binding signal appears to be low for this radioligand.   
 
We have recently reported the synthesis, in vitro and in vivo evaluation and 
radiosynthesis of a PET radioligand for the I2BS, 11C-BU99008 (13, 14).  In this 
manuscript, we report the preclinical in vivo evaluation of 11C-BU99008, for imaging 
I2BS, in rhesus monkey brain. 
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Materials and Methods 
Chemicals 
3H-BU99008 (SA=1.04TBq/mmol) was custom synthesised by Sibtech.  Challenge 
drugs moclobemide and lazabemide were obtained from commercial suppliers: 
Sigma-Aldrich Company Ltd. and Tocris Biosciences.  Dr Husbands synthesized 
the BU224.  All other chemicals and reagents were purchased from commercial 
suppliers and used without further purification. 
 
Animals 
All experiments in animals were carried out in accordance with the UK Animals 
(Scientific Procedures) Act 1986.  PET imaging experiments in rhesus monkeys 
were conducted in accordance with a protocol approved by the Yale University 
Institutional Animal Care and Use Committee.   
 
In Vitro Competition Binding Studies 
Membrane preparation, competition binding studies and data analysis were 
conducted as previously described (13) with the following alterations.  Rat (male, 
Wistar, 250-300g) and Cynomologus monkey brains were used and resulting 
membrane preparations stored at -80oC.  The displacement binding studies for the 
3H-BU99008 (1nM) were conducted at 37°C in assay buffer (50mM TRIS-HCl, 
140mM NaCl, 1.5mM MgCl2, 5mM KCl, 1.5mM CaCl2, pH7.4), and radioactivity was 
determined using a Tricarb 2900 β-counter.  Protein content was determined using 
a Pierce bicinchoninic acid kit.   
 
PET Imaging Studies in Rhesus Monkeys 
Radiochemistry. 11C-BU99008 was prepared by N-alkylation of the desmethyl 
precursor BU99007 with 11C-CH3I in the AutoLoop synthesis module (Bioscan).  A 
description of the synthetic methods can be found in supplementary information 
(Supplementary Figure 1 (supplemental materials are available online only at 
http://jnm.snmjournals.org)).  
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Study Design. Two Rhesus monkeys (Macaca mulatta; female, ~6kg, 7 years and 
female, ~7kg, 8 years) were used, with scanning days at least 14 days apart.  Each 
animal had five scanning days.  Each scanning day consisted of a baseline scan 
with 11C-BU99008 (120min); following this, animals received an i.v. injection of 
blocking drug over a 10min period, ~10min prior to initiation of a second scan with 
11C-BU99008 (120min), to determine binding specificity and selectivity of the 
radioligand (Supplementary Table 1).  Administration of the specific I2BS ligand, 
BU224, was: monkey one, 0.01, 0.03 and 0.3mg/kg, and monkey two, 0.01, 0.03, 
0.1mg/kg.  To assess the selectivity of binding to I2BS, both animals received an 
injection of the reversible MAOA inhibitor, moclobemide (1mg/kg) and the reversible 
MAOB inhibitor, lazabemide (0.5mg/kg). Data acquisition started simultaneously 
with ligand injection. Vital signs were monitored at least four times per hour, and 
more frequently following injection of tracer and blocking drugs. 
 
MRI Imaging. Images were acquired for each monkey on a Siemens 3.0-T Trio 
scanner, using an extremity coil.  T1-weighted images were acquired in the coronal 
plane with a spin-echo sequence (TE=3.34, TR=2530, flip angle=7°, section 
thickness=0.50mm, field of view=140mm, image matrix=256×256×176 pixels, 
matrix size=0.547×0.547×0.500mm).  Whole brain image was cropped to 
176×176×176 pixels using MEDx software (Medical Numerics) before 
co-registration with PET image data. 
 
PET Imaging Procedures. Animals were sedated with an intramuscular injection of 
ketamine hydrochloride (10±2mg/kg), ~2h prior to the start of scanning, transported 
to the PET facility, anaesthetized using isofluorane, intubated and maintained on 
oxygen and 1.5–2.5% isofluorane throughout the study.  PET scans were 
performed on the FOCUS 220 PET scanner (Siemens Preclinical Solutions), with a 
reconstructed image resolution of ~1.5mm.  Following a transmission scan, 
170±14MBq (4.6±0.4mCi; mass dose=0.08±0.02µg/kg) of 11C-BU99008 was 
injected over 3min.  List-mode data were acquired for 120min and binned into 
sinograms with the following frame timing: 6×30s; 3×1min; 2×2min; 22×5min.  
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Dynamic scan data were reconstructed with a filtered-back projection algorithm 
with corrections for attenuation, normalization, scatter, and randoms.   
 
Arterial Blood Sampling. Arterial blood samples were collected for the 
determination of: whole blood and plasma input functions, and metabolite analysis 
and plasma free fraction (fp) of 11C-BU99008.  These procedures are described in 
detail in the supplementary information. 
 
Regional Time-Activity Curve Computation. An existing region of interest (ROI) 
map defined on a template brain (a representative MR image of a rhesus brain) 
was used.  The following, a priori defined, ROI were examined: cingulate, frontal, 
insula, and occipital cortex, brainstem, pons, cerebellum, caudate, putamen, 
globus pallidus and thalamus.  A nonlinear transformation was estimated using the 
Bioimagesuite software (http://www.bioimagesuite.org/) to transfer the ROI 
template to the MR image of each animal used during this study.  These regions 
were then transferred to the PET images based on a rigid transformation matrix 
(15), and used to generate time-radioactivity curves (TAC).   
 
Kinetic Modeling. Regional TACs were analysed using one- and two-tissue 
compartment models (1TC and 2TC) and multi-linear analysis (MA1) (16) to 
calculate regional distribution volume (VT).  MA1 is a linear method related to 
Logan analysis, but with less noise-induced bias.  Like Logan analysis, data are 
fitted starting at a specified time, t*; here t*=20min.  The optimal model was based 
on quality of fit, and the uncertainty (standard error) of the VT parameter estimate.  
For blocking studies, since there was no suitable reference region, a graphical 
method was used to calculate the non-displaceable volume of distribution (VND) 
and global and regional receptor occupancy (17).  Receptor occupancy data from 
different blocking drug doses was fitted to a one-site binding Emax model where 
occupancy values (Occ) are plotted versus administered dose (d); where 
Occ = d/(d + ED50), in order to derive the blocking dose needed to induce 50% 
global receptor occupancy (ED50). Regional values were also derived from receptor 
occupancy calculated from the VT values at baseline and at various blocking doses 
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using the equation above modified to add a parameter to permit maximum 
reduction in VT of <100%, i.e., accounting for VND.  
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RESULTS 
In vitro Competition Binding Studies 
3H-BU99008 in vitro competition data demonstrated a two-site fit to the rodent 
brain with BU224 exhibiting an IC50(High) value of 50.5±12.9nM (Table 1), consistent 
with previous data (13).  In contrast, competition of BU224 in cynomologus brain 
yielded a single site fit with an IC50 value of 130.2±33.9nM (Table 1).  Competition 
of 3H-BU99008 from both rat and cynomologus brains by the MAOB inhibitor, 
lazabemide, exhibited very poor inhibition of binding and the MAOA inhibitor, 
moclobemide, showed no inhibition at the highest concentration used (Table 1). 
 
Radiochemistry 
Injection ready 11C-BU99008 was successfully synthesised with a chemical yield of 
32±17% (decay-corrected), radiochemical purity of >99%, and a specific activity of 
146±33MBq/nmol (3.95±0.90mCi/nmol, n=19) at the end of synthesis.  The identity 
of the radiolabelled product was confirmed by co-injection with a sample of 
authentic BU99008, which, under the same elution conditions, showed an identical 
retention time.  
 
In vivo Blood Data 
Free fraction (fP) of 11C-BU99008 in the plasma was high, at 0.68±0.07 (n=19).   
The amount of total radioactivity measured in plasma was similar between baseline 
scans and following administration of either the MAO inhibitors or the I2BS inhibitor 
(Figure 1A).  In addition, radio-HPLC analysis revealed 11C-BU99008, under 
baseline conditions, to be rapidly metabolised in plasma, with the parent compound 
representing about 50% of the total radioactivity 20min following administration 
(Figure 1B).  However, there was a small decrease in parent fraction of 
11C-BU99008 following administration of all three inhibitors compared with data 
acquired under baseline conditions, where the parent compound represented 
about 50% of the total radioactivity at 15min following administration (Figure 1B). 
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In vivo PET Studies 
Representative baseline PET images and corresponding TACs for 11C-BU99008 
uptake into the rhesus brain are given in Figures 2B and 3A, respectively.  
11C-BU99008 readily entered the brain with the highest uptake observed in the 
globus pallidus, caudate and thalamus, with moderate uptake in the cortical and 
putamen regions, and lowest uptake in the cerebellum and occipital cortex.  Peak 
radioactivity concentrations were observed approximately 15–25min after 
administration of 11C-BU99008, followed by a slow washout from all regions (Figure 
3A). 
 
The regional TACs were analysed by the reversible 1TC and 2TC models as well 
as by the MA1 model, (16).  The 2TC model produced good fits to the data, but 
over 20% of fits to baseline data had unreliable VT estimates, i.e., standard errors 
(%SE) >20%.  Poor reliability occurred most often in smaller, noisier regions and in 
baseline scans or scans with little effective blockade (see below).  The 1TC model 
showed clear lack of fit in most cases.  Also, the VT values from 1T underestimated 
those from 2TC by 10-40% (excluding 2TC values with high %SE), with the 
relationship of VT(1T)=0.87 × VT(2T) – 4.2, r2=0.92.  The MA1 method produced good 
fits and stable estimates for VT with small differences in VT values using different t* 
values from 20 and 40min.  In the cases where 2TC values had %SE <20%, the 
relationship between MA1 and 2TC values was VT(MA1)=0.94 × VT(2T) – 1.3, r2=0.97). 
Based on the bias from 1TC fits, and the numerous cases of high %SE from 2TC, 
MA1 with t*=20min, was chosen as the model of choice for derivation analysis. 
 
Table 2 lists MA1-derived regional VT values from individual baseline scans.  The 
baseline data acquired from the two rhesus monkeys were demonstrated to be 
reproducible and consistent throughout the course of the study (Figure 4).  Using 
the MA1 model with t*=20min, baseline VT values were highest in the globus 
pallidus (114.2±24.0mL/cm), caudate (109.7±13.7mL/cm) and thalamus 
(96.3±8.1mL/cm) and lowest in the cerebellum (48.1±4.8mL/cm).  This rank order 
of regional VT for 11C-BU99008 from the baseline data (globus 
pallidus>cortex>cerebellum, Table 2) is consistent with reported I2BS densities and 
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distribution determined by tissue-section autoradiography in humans (18) and in 
vivo pig PET (14).  Furthermore, the mean rhesus VT values were significantly 
correlated (r2=0.72; P<0.05) with the mean VT values from our previous in vivo 
porcine 11C-BU99008 PET data ((14) and unpublished data from the porcine study) 
(inset, Figure 4).  
 
In vivo blocking studies utilising the MAOA and MAOB inhibitors, moclobemide and 
lazabemide, respectively, did not cause any significant change in binding signal of 
11C-BU99008 to any regions studied (Figures 2C, 2E, and Supplementary Figure 2).  
In vivo competition using 11C-BU99008 plus increasing doses of the selective I2BS 
blocker, BU224, yielded a dose-dependent decrease in uptake of 11C-BU99008 in 
all regions studied. The highest dose administered (0.3mg/kg) yielded an apparent 
near-to-full blockade, suggesting high selectivity of this radioligand for the I2BS 
(Figures 2G, 3B, and 5, Table 3).  The presence of a dose-dependent decrease in 
binding in the cerebellum suggests this is not a suitable reference region for 
analysis of 11C-BU99008. 
 
A global receptor occupancy measure was calculated for the BU224 studies using 
the occupancy plot (17).  Occupancy values ranged from 25-35% for the lowest 
dose of BU224 (0.01mg/kg) to 93% for the highest dose (0.3mg/kg).  These 
occupancies were plotted vs. administered dose (d) in Figure 6 with a fit to the 
equation Occ = d/(d + ED50), which yielded an ED50 estimate of 0.022mg/kg for the 
whole brain (Table 3). 
 
Regional ED50 values for BU224 were also calculated for the globus pallidus, 
frontal cortex and cerebellum using the percentage reduction in VT instead of the 
estimated global occupancy value (Supplementary Figure 3A, B, C).  Calculated 
regional ED50 values were 0.017mg/kg for globus pallidus, 0.017mg/kg for frontal 
cortex, and 0.016mg/kg for the cerebellum (Supplementary Figure 3, Table 3).    
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DISCUSSION 
This paper describes the radiosynthesis of 11C-BU99008 and its characterisation 
as a novel PET radioligand for the quantification of central I2BS in vivo in rhesus 
monkeys.   
 
BU99008 was selected as the most suitable compound for radiolabelling with a 
PET radioisotope for imaging the I2BS, as reported previously by our group (13).  
In addition, BU99008 exhibited selectivity and nanomolar affinity for the I2BS in the 
rodent and cynomologus brain (Table 1).  Interestingly, a two-site model fit was 
preferred for the rodent and a one-site fit for the cynomologus brain tissue, 
suggesting that, in the rodent brain, BU99008 exhibits a degree of affinity for a 
second binding site which may be unrelated to the I2BS, possibly reflecting a 
monoamine oxidase binding component (19).  Importantly, due to the nature of the 
I2BS being co-localised with monoamine oxidases (MAO) on the outer membrane 
mitochondrial enzymes (20), it was essential to investigate the relative affinities of 
selective MAOA and MAOB inhibitors for the I2BS in order to proceed.  In vitro 
studies using cynomologus brain demonstrated MAO inhibitors to possess a low 
affinity for the I2BS in (Table 1).  However in the rodent brain tissue, the MAOB 
inhibitor possessed a similar affinity for the low affinity binding site exhibited 
previously in the rodent brain by BU224 (Table 1).  These data confirm the notion 
that the high affinity binding component, in vitro, in both the rat and cynomologus 
brain is expected to represent the I2BS. 
 
In view of these in vitro data, and combined with a successful radiolabelling 
feasibility assessment, we progressed the development of BU99008 as a PET 
ligand via evaluation in porcine brain, in vivo (14).  In that study, 11C-BU99008 
demonstrated reversible kinetics and a brain distribution consistent with the known 
binding site densities and localisation for the I2BS protein, and a dose-dependent 
decrease in VT following administration of the selective I2BS blocker, BU224.  
Further studies in pig showed a small, but relevant, binding component associated 
with MAO (manuscript in preparation).  Therefore, given that relative expression 
levels of I2BS and MAO differs from species to species, in order to progress 
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11C-BU99008 for use in human studies we decided to assess this PET ligand 
further, preclinically, in rhesus monkey, since we predict human brain uptake and 
in vivo binding characteristics of this particular PET ligand would be more similar to 
rhesus than porcine.  BU99008 was successfully radiolabelled with carbon-11 with 
good reproducibility, radiochemical yields and high specific activities.  
 
After injection into a rhesus monkey, the radioligand 11C-BU99008 metabolised 
fairly quickly, with only ~30% of parent compound remaining at 30min post 
injection.  A slight acceleration in metabolism was also observed when blocking 
agents were given before 11C-BU99008 injection but this effect was modest and 
unlikely to affect the usability of this ligand. 
 
In monkey brain 11C-BU99008 displayed differential regional uptake.  This 
heterogeneous distribution of 11C-BU99008 exhibited the following rank order: 
globus pallidus and other basal ganglia regions>cortex>cerebellum, consistent with 
the known I2BS densities and results from human tissue-section autoradiography 
(18) and porcine PET imaging experiments (14).  While the cerebellum showed the 
lowest brain uptake there was still a decrease in VT values after BU224 blockade 
(Figure 4), indicating cerebellum would be unsuitable as a reference region.  This 
was consistent with the findings of our previous study in pig (14).  
 
An assessment of the intra-subject variability was performed that yielded low to 
moderate variability in the VT values obtained for each ROI studied for each subject 
across multiple baseline scans (Figure 4).  Furthermore, comparison of inter-
species variability between the rhesus monkeys used in this study and pigs used 
previously by our group with this PET radioligand (14), demonstrated a significant 
correlation (inset, Figure 4), suggesting a degree of correspondence between 
these two species for the I2BS, albeit 11C-BU99008 appears to be affected by MAO 
inhibitors in the porcine which is a phenomenon not exhibited in the rhesus 
(manuscript in preparation). 
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The effects of the MAOA inhibitor, moclobemide, and the MAOB inhibitor, 
lazabemide, on 11C-BU99008 binding were determined in vivo, in rhesus monkey 
and found to cause no significant decrease in VT in any of the ROIs assessed 
(Supplementary Figure 2).  This key finding suggests that in rhesus monkey brain 
any contribution of the 11C-BU99008 signal due to binding to MAO is small or 
negligible and would not be expected to cause any significant interference with the 
assessment of I2BS binding signal in this species. 
 
Following administration of increasing blocking doses of BU224, a dose-dependent 
decrease in 11C-BU99008 VT was observed in all regions of the rhesus brain 
(Figure 5), confirming the absence of a reference region for this PET radioligand, 
and remaining consistent with the known distribution profile for I2BS in the brain.  
The dose-dependent decrease in VT observed for all ROI studied is not thought to 
represent a global change unrelated to the specific binding of 11C-BU99008 and 
the blocking by BU224 given that: (a) a heterogeneous signal was observed across 
the ROI under baseline conditions, (b) differential levels of decrease in VT values 
were observed for each region following increasing doses of BU224, and (c) a 
plateau at a VT value of ~20mL/cm was achieved for all ROI following the highest 
dose of BU224 administered (0.3mg/kg; Figure 5).  Additionally, the dose-
dependent blockade by the selective I2BS inhibitor in the rhesus brain confirmed 
the specificity of 11C-BU99008 for the I2BS and demonstrated a blockade of ~90% 
across all ROI at the highest dose administered (0.3mg/kg).  Interestingly, the in 
vivo ED50 of BU224 generated across all brain regions was consistent with the 
presence of one binding site and generated a value of 0.022mg/kg (Figure 6), 
which is consistent with the known in vitro and ex vivo properties of this compound 
(5).   
 
Given these data, we predict that 11C-BU99008 should demonstrate a similar 
binding distribution profile in the human brain to that observed from this study in 
rhesus monkey, where the rank order of regional brain uptake for this ligand would 
be expected to be globus pallidus>cortical regions>cerebellum.  For modelling 
purposes, since the multi-linear analysis method, MA1, consistently produced good 
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fits to the data along with reliable and stable estimates of VT for all regions of the 
rhesus brain studied, the use of this particular model for analysis of PET data 
generated using 11C-BU99008 should be considered in future studies.  Work is 
underway to assess the utility of 11C-BU99008 as a PET ligand for in vivo imaging 
and quantification of I2BS in the human population, and if deemed useful, its 
applicability for determining alterations in I2BS density and distribution in known 
disease states will be investigated.  
 
Conclusions 
This manuscript reports the radiolabelling and pharmacological investigation of 
11C-BU99008 as a novel I2BS PET radioligand in rhesus monkeys.  In vivo 
distribution of 11C-BU99008 in the rhesus monkey brain demonstrated the following 
rank order of regional uptake: globus pallidus>cortex>cerebellum, consistent with 
the known distribution profile of the I2BS.  11C-BU99008 displayed reversible 
kinetics and specificity for the I2BS, with the MA1 model representing the most 
appropriate analysis method for the derivation of binding parameters for this PET 
radioligand.  The data reported here provides evidence for 11C-BU99008 to 
represent a potentially useful PET imaging tool for probing the I2BS. Work is 
underway in order to progress 11C-BU99008 for assessment of its clinical utility as 
a PET radioligand for I2BS.   
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Tables 
Table 1.  In vitro I2BS binding affinities of the blocking drugs in rat and non-human 
primate brain using 3H-BU99008.   
 
Protein Target Blocking drug IC50±SD (nM) 
  Rat Cynomologus 
I2BS  BU224 50.5±12.9 (high) 130.2±33.9 
  9596±2494 (low)  
MAOA Moclobemide >100,000 >100,000 
MAOB Lazabemide 6445±1733 17370±2068 
 
Displacement of 3H-BU99008 by BU224 was best fit to a 2-site model in rat only, 
for all other instances the data was best fit to a 1-site model; (n=4). 
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Table 2. Baseline regional VT values (mL/cm) for 11C-BU99008 using MA1. Values 
are computed with t*=20min (n=8).  
 
Brain Region 
MA1 VT 
(Mean±SD) 
Globus Pallidus 114.2±24.0 
Caudate 109.7±13.7 
Thalamus 96.3±8.1 
Putamen 75.7±7.8 
Frontal Cortex 75.1±14.2 
Cingulate Cortex 85.5±13.0 
Occipital Cortex 50.5±7.3 
Insula Cortex 76.3±9.2 
Pons 70.1±6.9 
Brainstem 75.2±8.5 
Cerebellum 48.1±4.8 
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Table 3.  Calculated fraction of I2-BS occupied by BU224 using 11C-BU99008 
 
BU224 Dose Percentage Occupancy 
(mg/kg) Whole Brain 
Globus 
Pallidus 
Frontal 
Cortex 
Cerebellum 
0.01 35(1) 25(2) 38(1) 32(2) 32(1) 24(2) 30(1) 27(2) 
0.03 54(1)* 66(2) 50(1)* 61(2) 48(1)* 65(2) 47(1)* 54(2) 
0.1 81(2) 74(2) 73(2) 64(2) 
0.3 93(1) 85(1) 75(1) 72(1) 
ED50 0.022 0.017 0.017 0.016 
 
Number in parentheses indicates the animal used to derive the value: monkey 1, 
monkey 2.  Whole brain occupancy was calculated using the occupancy plot (17) 
and is derived from the slope for all reported brain regions.  Values calculated from 
the VT determined using the MA1 model. *Percentage occupancies generated from 
an averaged composite of baseline scans for monkey 1 due to failure to obtain a 
baseline scan on this study day. 
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Figure legends 
 
Figure 1.  Mean total plasma radioactivity (panel A) and metabolite data (panel B) 
for 11C-BU99008 scan.  Symbols represent: baseline scan data ; blocking scan 
data using MAO inhibitors ; blocking scan data using BU224 .  Each point 
represents the mean of all the scans in that group, vertical bars represent the 
standard deviation.  
 
Figure 2.  Representative coronal, transverse, and sagittal images of 11C-BU99008 
uptake in rhesus brain.  Images are summed from 30-45min following radioligand 
injection and are displayed as SUVs. A: structural MRI. B,C: baseline and 
moclobemide pre-block (1mg/kg). D,E: baseline and lazabemide pre-block 
(0.5mg/kg). F,G: baseline and BU224 pre-block (0.3mg/kg). Paired scans, (B,C), 
(D,E), and (F,G), were performed on the same day. 
 
Figure 3.  Representative time–activity curves for 11C-BU99008 in selected ROIs in 
rhesus brain. A: Baseline 11C-BU99008 scan. B: 11C-BU99008 scan after 
administration of BU224 (0.3mg/kg).  The symbols represent: Caudate ; 
Cerebellum ; Frontal cortex ; Globus pallidus ; Occipital cortex ; 
Putamen ; Thalamus .   
 
Figure 4.  Bar chart showing the regional distribution volume (VT) of 11C-BU99008 
from two animals (monkey 2, open and monkey 1, filled bars).  These represent the 
mean±SD from four separate baseline scans.  The insert shows the significant 
correlation (r2=0.72; P<0.05) between the mean VT from this study (both animals) 
and the pig (n=3; (14) and unpublished data from the pig study).  Regional VT 
values were generated using the MA1 model (t*=20min) for the rhesus data and 
the 1TC model for the porcine data. 
 
Figure 5.  Bar chart showing the regional distribution volume (VT) of 11C-BU99008 
and the effect of increasing doses of the I2BS ligand BU224: 0.01mg/kg (striped); 
24 
0.03mg/kg (chequered); 0.1mg/kg (clear); 0.3mg/kg (grey) and baseline (black).  
The bars represent the mean±SD; VT generated using the MA1 model. 
 
Figure 6.  Dose dependent occupancy by BU224 in whole brain, occupancy 
calculated using the occupancy plot (17) ED50=0.022mg/kg).  VT data generated 
using the MA1 model; monkey 1 , monkey 2 .   
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Figure 1.  Mean total plasma radioactivity (panel A) and metabolite data (panel B) 
for 11C-BU99008 scan.  Symbols represent: baseline scan data ; blocking scan 
data using MAO inhibitors ; blocking scan data using BU224 .  Each point 
represents the mean of all the scans in that group, vertical bars represent the 
standard deviation. 
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Figure 2.  Representative coronal, transverse, and sagittal images of 11C-BU99008 
uptake in rhesus brain.  Images are summed from 30-45min following radioligand 
injection and are displayed as SUVs. A: structural MRI. B,C: baseline and 
moclobemide pre-block (1mg/kg). D,E: baseline and lazabemide pre-block 
(0.5mg/kg). F,G: baseline and BU224 pre-block (0.3mg/kg). Paired scans, (B,C), 
(D,E), and (F,G), were performed on the same day. 
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Figure 3.  Representative time–activity curves for 11C-BU99008 in selected ROIs in 
rhesus brain. A: Baseline 11C-BU99008 scan. B: 11C-BU99008 scan after 
administration of BU224 (0.3mg/kg).  The symbols represent: Caudate ; 
Cerebellum ; Frontal cortex ; Globus pallidus ; Occipital cortex ; 
Putamen ; Thalamus .    
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Figure 4.  Bar chart showing the regional distribution volume (VT) of 11C-BU99008 
from two animals (monkey 2, open and monkey 1, filled bars).  These represent the 
mean±SD from four separate baseline scans.  The insert shows the significant 
correlation (r2=0.72; P<0.05) between the mean VT from this study (both animals) 
and the pig (n=3; {Kealey, 2013 #910} and unpublished data from the pig study).  
Regional VT values were generated using the MA1 model (t*=20min) for the rhesus 
data and the 1TC model for the porcine data. 
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Figure 5.  Bar chart showing the regional distribution volume (VT) of 11C-BU99008 
and the effect of increasing doses of the I2BS ligand BU224: 0.01mg/kg (striped); 
0.03mg/kg (chequered); 0.1mg/kg (clear); 0.3mg/kg (grey) and baseline (black).  
The bars represent the mean±SD; VT generated using the MA1 model. 
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Figure 6.  Dose dependent occupancy by BU224 in whole brain, occupancy 
calculated using the occupancy plot {Cunningham, 2010 #900} ED50=0.022mg/kg).  
VT data generated using the MA1 model; monkey 1 , monkey 2 .   
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